Recurrent small cell lung cancer: update

Semin Oncol. 2003 Feb;30(1):72-8. doi: 10.1053/sonc.2003.50014.

Abstract

Small cell lung cancer continues to recur and claim the lives of most of its victims. Thus, management of the patient with recurrent disease remains an active area of research. This review provides an update of clinical research experience over the past decade with relatively new conventional cytotoxins in this setting, such as the topoisomerase I inhibitors and the taxanes. Additionally, novel molecular targeted approaches with specific relevance for small cell lung cancer are discussed.

Publication types

  • Review

MeSH terms

  • Animals
  • Antineoplastic Agents / therapeutic use*
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use
  • Carcinoma, Small Cell / drug therapy*
  • Carcinoma, Small Cell / therapy
  • Clinical Trials as Topic
  • Gefitinib
  • Humans
  • Immunotoxins / therapeutic use*
  • Lung Neoplasms / drug therapy*
  • Lung Neoplasms / therapy
  • Neoplasm Recurrence, Local / drug therapy*
  • Neoplasm Recurrence, Local / therapy
  • Oligonucleotides, Antisense / therapeutic use*
  • Prognosis
  • Quinazolines / therapeutic use
  • Thionucleotides / therapeutic use

Substances

  • Antineoplastic Agents
  • Immunotoxins
  • Oligonucleotides, Antisense
  • Quinazolines
  • Thionucleotides
  • oblimersen
  • Gefitinib